Barclays reiterated their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note released on Monday morning, Digital Look reports. The firm currently has a GBX 1,900 ($24.99) price objective on the stock.
Several other research firms have also issued reports on HIK. Peel Hunt restated a hold rating on shares of Hikma Pharmaceuticals in a research report on Friday, January 10th. HSBC restated a reduce rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 27th. Morgan Stanley restated an equal weight rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 13th. Jefferies Financial Group restated a buy rating on shares of Hikma Pharmaceuticals in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. upped their price target on shares of Hikma Pharmaceuticals from GBX 1,800 ($23.68) to GBX 1,850 ($24.34) and gave the company a neutral rating in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,853.33 ($24.38).
LON HIK opened at GBX 1,936.50 ($25.47) on Monday. The company has a 50-day simple moving average of GBX 1,954.34 and a two-hundred day simple moving average of GBX 1,949.86. The company has a quick ratio of 0.78, a current ratio of 1.28 and a debt-to-equity ratio of 37.69. Hikma Pharmaceuticals has a 12-month low of GBX 1,491.50 ($19.62) and a 12-month high of GBX 2,212 ($29.10). The firm has a market cap of $4.69 billion and a price-to-earnings ratio of 13.01.
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Featured Story: How can you know how many shares are floating?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.